142 related articles for article (PubMed ID: 11449334)
21. Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying.
Santana H; Sotolongo J; González Y; Hernández G; Chinea G; Gerónimo H; Amarantes O; Beldarraín A; Páez R
Biologicals; 2014 Nov; 42(6):322-33. PubMed ID: 25190208
[TBL] [Abstract][Full Text] [Related]
22. The formulation of recombinant factor IX: stability, robustness, and convenience.
Bush L; Webb C; Bartlett L; Burnett B
Semin Hematol; 1998 Apr; 35(2 Suppl 2):18-21. PubMed ID: 9565162
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.
Kelley BD; Tannatt M; Magnusson R; Hagelberg S; Booth J
Biotechnol Bioeng; 2004 Aug; 87(3):400-12. PubMed ID: 15281114
[TBL] [Abstract][Full Text] [Related]
24. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
25. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
[TBL] [Abstract][Full Text] [Related]
26. Stability of factor VIII concentrates after reconstitution.
Schulman S; Gitel S; Martinowitz U
Am J Hematol; 1994 Mar; 45(3):217-23. PubMed ID: 8296792
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.
Stieltjes N; Altisent C; Auerswald G; Négrier C; Pouzol P; Reynaud J; Roussel-Robert V; Savidge GF; Villar A; Schulman S
Haemophilia; 2004 Sep; 10(5):452-8. PubMed ID: 15357770
[TBL] [Abstract][Full Text] [Related]
28. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
Josephson CD; Abshire T
Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
[TBL] [Abstract][Full Text] [Related]
29. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
30. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
31. Loss of factor VIII activity during storage in PVC containers due to adsorption.
McLeod AG; Walker IR; Zheng S; Hayward CP
Haemophilia; 2000 Mar; 6(2):89-92. PubMed ID: 10781194
[TBL] [Abstract][Full Text] [Related]
32. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations.
Page C; Dawson P; Woollacott D; Thorpe R; Mire-Sluis A
J Pharm Pharmacol; 2000 Jan; 52(1):19-26. PubMed ID: 10716599
[TBL] [Abstract][Full Text] [Related]
33. Recombinant factor VIII SQ--the influence of formulation parameters on structure and surface adsorption.
Fatouros A; Sjöström B
Int J Pharm; 2000 Jan; 194(1):69-79. PubMed ID: 10601686
[TBL] [Abstract][Full Text] [Related]
34. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients.
Courter SG; Bedrosian CL
Semin Hematol; 2001 Apr; 38(2 Suppl 4):52-9. PubMed ID: 11449336
[TBL] [Abstract][Full Text] [Related]
36. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII.
Mikaelsson M; Oswaldsson U; Jankowski MA
Semin Hematol; 2001 Apr; 38(2 Suppl 4):13-23. PubMed ID: 11449331
[TBL] [Abstract][Full Text] [Related]
37. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.
Sandberg H; Almstedt A; Brandt J; Gray E; Holmquist L; Oswaldsson U; Sebring S; Mikaelsson M
Thromb Haemost; 2001 Jan; 85(1):93-100. PubMed ID: 11204595
[TBL] [Abstract][Full Text] [Related]
38. Investigations into, and development of, a lyophilized and formulated recombinant human factor IX produced from CHO cells.
Almeida AG; Pinto RCV; Smales CM; Castilho LR
Biotechnol Lett; 2017 Aug; 39(8):1109-1120. PubMed ID: 28484912
[TBL] [Abstract][Full Text] [Related]
39. Influence of phospholipids on the assessment of factor VIII activity.
Mikaelsson M; Oswaldsson U; Sandberg H
Haemophilia; 1998 Jul; 4(4):646-50. PubMed ID: 9873808
[TBL] [Abstract][Full Text] [Related]
40. Freeze-dried activated substrate for factor VIII assays.
Margolis J
Dev Biol Stand; 1987; 67():163-7. PubMed ID: 3111909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
